Dyspnea Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

Dyspnea Treatment Market is segmented By Treatment Type (Therapy (Supplemental Oxygen Therapy, Relaxation Therapy), Drugs (Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids, Others), End-user (Hospitals, Home Care, Specialty Centers, Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

Dyspnea Treatment Industry Overview

Dyspnea Treatment Market Summary
Study Period: 2018 - 2028
Fastest Growing Market: North America
Largest Market: Asia-Pacific
CAGR: 4.5 %

Major Players

Dyspnea Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order


80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Dyspnea Treatment Market Analysis

Dyspnea Treatment Market is expected to grow at a registered CAGR of 4.5% during the forecast period.

According to the study titled "Dyspnea: The vanished warning symptom of COVID‐19 pneumonia" published in November 2020, dyspnea is slightly more common in patients who develop acute SARS-CoV-2 infection and have the worst clinical outcomes. In the general population, in people with chronic obstructive pulmonary disease, dyspnea has been strongly linked to a poor prognosis. Moreover, as per the same source, less than 50% of SARS-COV-2 infected patients had been reported to experience dyspnea, a subjective feeling of breathing discomfort. As a result, it was anticipated that demand for dyspnea treatments would increase; however, because of a weak supply chain, the market suffers during a pandemic

The increase in the prevalence of COPD and asthma, which are the main causes of dyspnea and its causative symptoms, is what is driving the global market for dyspnea treatments. The main causes of dyspnea are a high prevalence of cardiopulmonary diseases, a rise in obesity among people, and alterations in lifestyle. According to the study titled "Prevalence and severity of different dimensions of breathlessness among elderly males in the population" published in the European Respiratory Journal in February 2022, breathlessness has been a common symptom of cardiorespiratory disease, as well as a prevalent symptom in the general population. Shortness of breath affects 10-25% of adults in their middle years and older during regular activity. Therefore, increasing dyspnea prevalence is anticipated to result in increased demand for its management and treatment, which will propel market expansion. Additionally, COPD and asthma are the main contributors to dyspnea, and the rising prevalence of these conditions will fuel market expansion over the forecast period. According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), that affects both children and adults. Globally, around 262 million people had asthma in 2020, which is expected to boost the demand of dyspnea treatment among people suffering from Asthma.

Furthermore, the global market for dyspnea treatments is expanding as a result of rising air pollution levels and toxicity exposure that causes breathlessness in the populace. According to the United States Environmental Protection Agency in June 2022, health could be negatively impacted by ozone in the air, especially on hot, sunny days when ozone levels could rise dangerously high. People with asthma, children, elderly people, and those who engage in outdoor activities were at risk from breathing ozone-containing air. Thus, increasing exposure to toxic substances and air pollution may significantly increase the likelihood of developing dyspnea, fueling the market growth over the projected period.

Thus, all aforementioned factors are expected to boost the market growth over the forecast period, however, the high cost associated with the treatment may restrain the market growth.

Dyspnea Treatment Industry Segments

As per the scope of the report, dyspnea, also referred to as air hunger, is characterized as shortness of breath. Mild, transient, serious, and persistent shortness of breath is all possible. Dyspnea can be brought on by excessive exertion, spending time at high altitudes, and a variety of other conditions. Dyspnea Treatment Market is segmented By Treatment Type (Therapy (Supplemental Oxygen Therapy, Relaxation Therapy), Drugs (Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids, Others), End-user (Hospitals, Home Care, Specialty Centers, Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

By Treatment type
By Therapy
Supplemental Oxygen Therapy
Relaxation Therapy
By Drug Class
Antianxiety Drugs
Anticholinergic Agents
By End User
Home Care
Specialty Centers
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Rest of the World

Report scope can be customized per your requirements. Click here.

Dyspnea Treatment Market Trends

This section covers the major market trends shaping the Dyspnea Treatment Market according to our research experts:

Supplemental Oxygen Therapy is Expected to Witness Healthy Growth Over the Forecast Period

Supplemental oxygen is the use of oxygen as a medicinal treatment. Acute indications for therapy include hypoxemia, carbon monoxide poisoning, and cluster headache. It may also be administered prophylactically to maintain blood oxygen levels during anesthesia induction.

Patients with other chronic lung diseases such as dyspnea are frequently prescribed oxygen therapy because it improves the quality of life and increases survival in hypoxemic patients with chronic obstructive pulmonary disease (COPD). According to the study titled "Long-term supplemental oxygen therapy" by Rick Carter published in March 2022, in the United States, 1.5 million patients received oxygen therapy each year. Thus, it is anticipated that the market will grow during the forecast period due to the rising trend of using oxygen therapy for respiratory conditions, including dyspnea.

According to the study titled "Administration of Supplemental Oxygen" published in the New England Journal of Medicine in July 2021, the study reported that supplemental oxygen is the most effective component in the treatment of dyspnea. Supplemental oxygen therapy improves sleep, mood, mental clarity, endurance, and the ability of people with some types of lung disease to perform regular, everyday tasks. In patients with severe lung diseases, additional oxygen therapy helps prevent heart failure. As a result of the additional advantages of oxygen therapy, the market is anticipated to expand throughout the forecast period.

Growing funding for oxygen therapy support is anticipated to accelerate the segment's growth. For instance, in June 2022, the United States Agency for International Development (USAID) has advanced plans for a previously announced USD 50 million investment to increase access to medical oxygen worldwide, beginning with commitments to build and enhance health care infrastructure to support bulk liquid oxygen in 50 facilities around the world. According to estimates from USAID, the investment will support the provision of medical oxygen at more than 20,000 beds, allowing thousands of patients to receive oxygen therapy every year. Moreover, the Global Fund invested around USD 600 million to help more than 80 lower-middle-income countries increase patient access to medical oxygen, and the United States is the fund's single-largest donor. Such government initiatives lower the cost for the patient population, which ultimately accelerates the segment's growth.

Thus, owing to the above factors the segment is expected to show a healthy growth rate over the forecast period.

Dyspnea Treatment Market : Estimated Number of Cases of Asthma Among Senior Citizen (in Million), India, 2020-2050

North America is Expected to Hold a Significant Market Share Over the Forecast Period

North America dominated the global dyspnea treatment market due to the presence of major market players, an increase in product approvals, a developed health care system, and a high prevalence of obesity and cardiopulmonary diseases.

According to the study titled "Respiratory Symptoms among US Adults: A Cross-Sectional Health Survey Study" published in Pulmonary Therapy in July 2022, the most common respiratory symptom, followed by a productive cough and shortness of breath, affects 17% of adult Americans every year. Morbid obesity was the most common comorbidity in subjects reporting this symptom, even though asthma, chronic obstructive pulmonary disease (COPD), and coronary heart disease were common causes of dyspnea on exertion. Moreover, the growing prevalence of these diseases is expected to boost the market growth. As per the Office of Disease Prevention and Health Promotion (ODPHP) 2020, more than 25 million people in the United States had asthma and approximately 14.8 million adults have been diagnosed with COPD.

Additionally, it is anticipated that a growing air population and harmful toxins will support market expansion. The United States Environmental Protection Agency in June 2022, in the United States, approximately 67 million tons of pollution were released into the atmosphere in 2021. These emissions primarily cause ozone and particle formation, acid deposition, and reduced visibility. this might result in several respiratory conditions, like breathing difficulties (dyspnea).

A growing number of clinical trials are anticipated to introduce better treatment options for diseases, which is anticipated to spur market expansion. According to the Clinitrials.gov updates in February 2022, the study titled "Dexamethasone in Controlling Dyspnea in Patients with Cancer" by the National Cancer Institute (NCI), the study has accessed the effectiveness of dexamethasone in managing dyspnea in cancer patients. In cancer patients, dexamethasone may enhance lung function, reduce dyspnea (shortness of breath), and enhance the quality of life. So, it may be anticipated that this will launch soon and aid in the expansion of the market under consideration.

Thus, owing to all above-mentioned factors the market is expected to witness high growth

Dyspnea Treatment Market - Growth Rate By Region

Dyspnea Treatment Market Competitor Analysis

The market studied is a consolidated market owing to the presence of a few major market players. With the rising technological advancements and product innovations, mid-size and small-scale companies are increasing their market presence by introducing new devices into the market at competitive prices. Some of the market players are Mayne Pharma Group Limited, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline, Hikma Pharmaceuticals plc, and others.

Dyspnea Treatment Market Top Players

  1. Mayne Pharma Group Limited

  2. Hikma Pharmaceuticals plc

  3. Lannett Company, Inc.

  4. GlaxoSmithKline

  5. Teva Pharmaceutical Industries Ltd

*Disclaimer: Major Players sorted in no particular order

Dyspnea Treatment Market Concentration

Dyspnea Treatment Market Recent Developments

  • In July 2022, OMRON Healthcare introduced its latest advancement in the Oxygen therapy category with the launch of a portable oxygen concentrator. The product is designed to aid the homecare providers when managing the therapy and lifestyle needs of nearly all patients with COPD and respiratory problems.
  • In May 2022, Max ventilator has launched the multifunctional noninvasive ventilators which come with the inbuild oxygen therapy and humidifier.

Dyspnea Treatment Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising in Prevalence of Dyspnea and its Associated Disorders

      2. 4.2.2 Increasing Levels of Air Pollution and Exposure to Various Toxins

    3. 4.3 Market Restraints

      1. 4.3.1 High Costs Associated with The Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 5.1 By Treatment type

      1. 5.1.1 By Therapy

        1. Supplemental Oxygen Therapy

        2. Relaxation Therapy

      2. 5.1.2 By Drug Class

        1. Antianxiety Drugs

        2. Antibiotics

        3. Anticholinergic Agents

        4. Corticosteroids

        5. Others

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Home Care

      3. 5.2.3 Specialty Centers

      4. 5.2.4 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Rest of the World


    1. 6.1 Company Profiles

      1. 6.1.1 Mayne Pharma Group Limited

      2. 6.1.2 Teva Pharmaceutical Industries Ltd.

      3. 6.1.3 GlaxoSmithKline plc

      4. 6.1.4 Bausch Health Companies Inc.

      5. 6.1.5 Hikma Pharmaceuticals plc

      6. 6.1.6 Lannett Company, Inc.

      7. 6.1.7 Amneal Pharmaceuticals LLC

      8. 6.1.8 Viatris Inc. (Mylan N.V.)

      9. 6.1.9 Lupin Limited

      10. 6.1.10 Akron Incorporated

      11. 6.1.11 ANI Pharmaceuticals, Inc.

      12. 6.1.12 Pfizer, Inc.

      13. 6.1.13 Sun Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Dyspnea Treatment Market Research FAQs

The Global Dyspnea Treatment Market is studied from 2018 - 2028.

The Global Dyspnea Treatment Market is growing at a CAGR of 4.5% over the next 5 years.

North America is growing at the highest CAGR over 2018 - 2028.

Asia-Pacific holds highest share in 2021.

Mayne Pharma Group Limited, Hikma Pharmaceuticals plc, Lannett Company, Inc., GlaxoSmithKline, Teva Pharmaceutical Industries Ltd are the major companies operating in Global Dyspnea Treatment Market.

Global Dyspnea Treatment Industry Reports

In-depth industry statistics and market share insights of the Global Dyspnea Treatment Market sector for 2020, 2021, and 2022. The Global Dyspnea Treatment Market research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Global Dyspnea Treatment Market report PDF.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!